View Item 

Show simple item record

Preserving ovarian function in patients receiving cyclophosphamide

dc.contributor.authorSlater, C. A.en_US
dc.contributor.authorLiang, M. H.en_US
dc.contributor.authorMcCune, J.en_US
dc.contributor.authorChristman, Gregory M.en_US
dc.contributor.authorLaufer, M.en_US
dc.date.accessioned2010-04-14T13:32:27Z
dc.date.available2010-04-14T13:32:27Z
dc.date.issued1999en_US
dc.identifier.citationSlater, C; Liang, M; McCune, J; Christman, G; Laufer, M (1999). "Preserving ovarian function in patients receiving cyclophosphamide." Lupus 8(1): 3-10. <http://hdl.handle.net/2027.42/68327>en_US
dc.identifier.issn0961-2033en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/68327
dc.format.extent3108 bytes
dc.format.extent200432 bytes
dc.format.mimetypetext/plain
dc.format.mimetypeapplication/pdf
dc.publisherSage Publicationsen_US
dc.titlePreserving ovarian function in patients receiving cyclophosphamideen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Rheumatology, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationumDivision of Obstetrics and Gynecology, University of Michigan Medical Center, University of Michigan Medical School, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherDepartment of Medicine, Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USAen_US
dc.contributor.affiliationotherDepartment of Medicine, Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USAen_US
dc.contributor.affiliationotherDivision of Gynecology, Department of Surgery, Division of Adolescent/Young Adult Medicine, Department of Medicine, Children's Hospital; Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/68327/2/10.1191_096120399678847335.pdf
dc.identifier.doi10.1191/096120399678847335en_US
dc.identifier.sourceLupusen_US
dc.identifier.citedreferenceSteinberg AD, Steinberg SC. Long term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone alone. Arthritis Rheum 1991; 34 (8): 945–950.en_US
dc.identifier.citedreferenceBalow JW, et al. Lupus nephritis. Ann Intern Med 1987; 106: 79–94.en_US
dc.identifier.citedreferenceBoumpas DT, et al. Controlled trial of pulse methyl prednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741–745.en_US
dc.identifier.citedreferenceLevey AS, et al.. The Lupus Nephritis Collaborative Study Group. Progression and remission of renal disease in the lupus nephritis collaborative study. Ann Intern Med 1992; 116: 114–123.en_US
dc.identifier.citedreferenceWang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11–14.en_US
dc.identifier.citedreferenceBelmont HM, Storch M, Buyon J. Abramson S. New York University/Hospital for Joint Disease experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995; 4: 104–108.en_US
dc.identifier.citedreferenceMontz FJ, Wolff AJ, Gambone, JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res 1991; 51: 2124–2126.en_US
dc.identifier.citedreferenceKlippel JH. Cyclophosphamide: ovarian and other toxicities. Lupus 1995; 4: 1–2.en_US
dc.identifier.citedreferenceBoumpas DT et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366–369.en_US
dc.identifier.citedreferenceLangevitz P, Klein L, Pras M. Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992; 28: 157–580.en_US
dc.identifier.citedreferenceRoubenoff R. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988; 18 (2): 88–110.en_US
dc.identifier.citedreferenceKarashima T, Zalatni A, Schally AV. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats. Proc Natl Acad Sci USA 1988; 85: 2329–2333.en_US
dc.identifier.citedreferenceTummon IS, et al. A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertil Steril 1989; 51: 390–394.en_US
dc.identifier.citedreferenceAtaya KM et al. A luteinizing hormone-relating agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985; 45: 2651–2656.en_US
dc.identifier.citedreferenceAtaya KM, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365–372.en_US
dc.identifier.citedreferenceAtaya KM, Pydyn E, Ramahi-Ataya, Orton CG. Is radiation induced ovarian failure in rhesus monkeys preventable by luteinizing hormonexs releasing hormone agonists? J Clin Endocrinol Metals 1995; 80 (3): 790–794.en_US
dc.identifier.citedreferenceDlugi AM, Miller JD, Knittle J, Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril 1990; 54: 419–426.en_US
dc.identifier.citedreferenceLemay A, Surrey ES, Friedman AJ. Extending the use of gonadotropinreleasing hormone agonists. The emerging role of steroid and nonsteroid agents. Fertil Steril 1994; 61 (1): 21–34.en_US
dc.identifier.citedreferenceFriedman AJ, et al. for the Leuprolide Study Group. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multi center study. Obstet Gynecol 1991; 77: 720–725.en_US
dc.identifier.citedreferenceFogelman, I. Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 1992; 57: 715–724.en_US
dc.identifier.citedreferenceScialli AR, Jestila KJ, Simon JA. Leuprolide acetate and bone mineral density measured by quantitive radiography. Fertil Steril 1993; 59 (3): 674–676.en_US
dc.identifier.citedreferenceJohansen JS, et al. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocrinol Metab 1988; 67: 701–706.en_US
dc.identifier.citedreferenceBarbieri RL, Friedman AJ. Gonadotropin Releasing Hormone Analogs. New York: Elsevier Science, 51, 1991.en_US
dc.identifier.citedreferencePlosker GL, Brogden RN. Leuprorelin. Drugs 1994; 48 (6): 930–967.en_US
dc.identifier.citedreferenceTobback C, Hugh S, Foote RH. A procedure for cyropreservation of hamster oocytes yielding highly conserved oocytes suitable for sperm penetration tests. Fertil Steril 1991; 55 (1): 184–188.en_US
dc.identifier.citedreferenceHammitt DG. Conditions of oocyte storage and use of noninseminated as compared with inseminated non fertilized oocytes for the hemizona assay. Fertil Steril 1993; 60: 131–163.en_US
dc.identifier.citedreferenceHarp R et al. Cryopreservation of murine ovarian tissue. Cryobiol 1994; 31: 336–343.en_US
dc.identifier.citedreferenceGook DA, Osborn SM, Bourne H, Johnson WIH. Fertilization of human oocytes following cyropreservation: normal karyotypes and absence of stray chromosomes. Hum Reprod 1994; 9 (4): 684–691.en_US
dc.identifier.citedreferenceHunter JL. Cryopreservation of human prophase I oocytes collected from unstimulated follicles. Fertil Steril 1994; 61 (6): 1077–1082.en_US
dc.identifier.citedreferenceToth TL et al. Cryopreservation of human prophase I oocytes collected from unstimulated follicles. Fertilization and in vitro development of cryopreserved human prophase I oocytes. Fertil Steril 1994; 61 (5): 891–894.en_US
dc.identifier.citedreferenceGutmann JN. Cancer and infertility. Infertil Reprod Med Clin North Am 1996; 7 (3): 935–952.en_US
dc.identifier.citedreferenceAtaya KM, Valeriote FA, Ramahi-Ataya AJ. Effect of cyclophosphamide on the immature rat ovary. Cancer Res 1989; 49: 1660–1664.en_US
dc.identifier.citedreferenceHochberg MC. Bisphosphonates in the treatment of osteoporosis. J Clin Rheumatol 1997; 3: 537–539.en_US
dc.identifier.citedreferencePetri M, Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1997; 40 (5): 797–803.en_US
dc.identifier.citedreferenceArden NK, Lloyd ME, Spector TD, Hughes GRV. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994; 3: 11–13.en_US
dc.identifier.citedreferenceBuyon JP et al Can women with systemic lupus erythematousus safely use exogenous estrogens? J Clin Rheumatol 1995; 1 (4): 205–212.en_US
dc.identifier.citedreferenceLeather AT, Studd JWW, Watson NR, Holland EFN. The prevention of bone loss in young women treated with GNRHa analogues with ‘add back’ estrogen therapy. Obstet Gynecol 1993; 81 (1): 104–107.en_US
dc.identifier.citedreferenceLaufer MR, et al. Inducing amenorrhea during bone marrow transplantation. J Reprod Med 1997; 42 (9): 537–541.en_US
dc.identifier.citedreferenceDamario MA, Rock JA. Gosrelin (Zoladex) versus danazol for endometriosis: the North American experience. B J Obstet Gyanecol 1994; 101 (S10): S13–S18.en_US
dc.identifier.citedreferenceLaufer MR, Rein MS. Treatment of abnormal uterine bleeding with gonadotropin-releasing hormone analogues. Clin Obstet Gynecol 1993; 36 (3): 668–678.en_US
dc.identifier.citedreferenceHenzl MR. Gonadotropin-releasing hormone and its analogues: from laboratory to bedside. Clin Obstet Gynecol 1993; 36 (3): 617–635.en_US
dc.identifier.citedreferenceNewton H et al. Low temperature storage and grafting of human ovarian tissue. Hum Reprod 1996; 11 (7): 1487–1491.en_US
dc.identifier.citedreferenceZhang J et al. Extracorporeal development and ultrarapid freezing of human fetal ova. J Assist Reprod Gent 1995; 12 (6): 361–368.en_US
dc.identifier.citedreferenceDawood MY, Ramos J, Khan-Dawood FS. Depot Leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil Steril 1995; 63 (6): 1177–1183.en_US
dc.identifier.citedreferenceFogelman I, et al. Goserelin (Zoladex) and the skeleton. Br J Obstet Gynaecol 1994; 101 (S10): S19–S23.en_US
dc.identifier.citedreferenceChapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkins disease. Blood 1981; 58 (4): 849–851.en_US
dc.identifier.citedreferenceGradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 1989; 16 (5): 425–436.en_US
dc.identifier.citedreferenceBermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995; 38 (12): 1722–1732.en_US
dc.identifier.citedreferenceHovatta O, et al. Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as cryoprotectants. Hum Reprod 1996; 11 (6): 1268–1272.en_US
dc.identifier.citedreferenceCandy CJ, Wood MJ Whittingham DG. Follicular development in cryopreserved marmoset ovarian tissue after transplantation. Hum Reprod 1995; 10 (9): 2334–2338.en_US
dc.identifier.citedreferenceCox SL, Shaw J, Jenkin G. Transplantation of cryopreserved fetal ovarian tissue to adult recipient in mice. J Reprod Fertil 196; 107: 315–322.en_US
dc.identifier.citedreferenceGosden RG, Baird DT, Wade JC, Webb R. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at — 196°C. Human Reprod 1994; 9 (4): 597–603.en_US
dc.identifier.citedreferenceRamsey-Goldman R, et al. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J. Rheumatol 1993; 20 (4): 1152–1157.en_US
dc.identifier.citedreferenceKovarsky J. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum 1983; 12 (4): 359–371.en_US
dc.identifier.citedreferenceSanders JE et al. Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation 1983; 36 (3): 252–255.en_US
dc.identifier.citedreferenceClements PJ, Davis, J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin. Arthritis Rheum 1986; 15 (4): 231–254.en_US
dc.identifier.citedreferenceWarne GL, Fairley KF, Horbs JB, Martin FIR. Cyclophosphamideinduced ovarian failure. N Eng J Med 1973; 289: 1159–1162.en_US
dc.identifier.citedreferenceRivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988; 259: 2123–2125.en_US
dc.identifier.citedreferenceCann CE et al. Reversible bone loss is produced by the GNRHa agonist nafarelin. In: Cohn DV, Martin TJ, Meunier A (eds). Calcium Regulation and Bone Metabolism. Amsterdam: Elsevier Science, 1987, 123–127.en_US
dc.identifier.citedreferenceLahita RG, Bucala R, Bralow HL, Fishman J. Determination of 16 alpha-hydroxyesterone by radioimmunoassay in systemic lupus erythematosus. Arthritis Rheum 1985; 18: 1122–1127.en_US
dc.identifier.citedreferenceSanchez-Guerrero J, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40 (5): 804–808.en_US
dc.identifier.citedreferenceMartin F, et al. Side effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254–257.en_US
dc.identifier.citedreferenceKoyama H, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39: 1403–1409.en_US
dc.identifier.citedreferencePolak de Fried E, et al. Pregnancy after human donor oocyte cryopreservation and thaw in association with intracytoplasmic sperm injection in a patient with ovarian failure. Fertil Steril 1998; 69 (3): 555–557.en_US
dc.identifier.citedreferenceAtaya KM et al. Inhibition of rat ovarian [3H] thymidine uptake by luteinizing hormone releasing hormone agonists: a possible mechanism for preventing damage by cytotoxic agents. Cancer Res 1988; 48: 7252–7256.en_US
dc.identifier.citedreferenceBlumenfeld Z, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropinreleasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620–1626.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10.1191_096120399678847335.pdf
Size:
195.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.